PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer’s DNA Vaccine

PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer’s DNA Vaccine




PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer’s DNA Vaccine

Delivered exclusively with the PharmaJet Needle-free System

GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, the Institute for Molecular Medicine (IMM) was awarded a $12 million grant from the National Institute on Aging (NIA) division of the National Institutes of Health (NIH). The grant supports clinical trials of their beta-amyloid vaccines based on DNA and recombinant protein for the prevention of Alzheimer’s disease (AD). A phase 1 clinical study in the U.S. is expected to begin in second quarter 2022 and the vaccine will be exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.

Alzheimer’s is a progressive brain disease that impacts 6.5 million Americans aged 65 and older. Moreover, currently 47 million people in the U.S. with asymptomatic preclinical Alzheimer’s disease are off the radar of the pharmaceutical industry. There are several drugs and vaccines in the clinical development that have shown limited clinical results in the fight against it. In 2022, the total national cost of caring for people living with Alzheimer’s and other dementias is projected to reach $321 billion.1 Up until now, AD therapeutics have mostly focused on treating the underlying pathology after the disease has taken hold. But once pathology begins and neurons are damaged, it becomes impossible to stop the disease. Current data suggest that an immunogenic preventive vaccine could induce high levels of antibodies inhibiting aggregation of Aβ in cognitively unimpaired people at risk of AD and delaying the disease onset.

Chris Cappello, President and CEO, PharmaJet commented, “We are pleased to be partnering with IMM in this important clinical trial and adding Alzheimer’s disease to our growing nucleic-acid-based R&D pipeline. Studies have demonstrated that delivery with the PharmaJet Tropis System has improved vaccine effectiveness.”

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Alzheimer’s Association. 2022 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2022;18. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

About PharmaJet

PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. PharmaJet’s Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.

About IMM

The Institute for Molecular Medicine (IMM) is a non-profit organization created with the goal of understanding, preventing and curing chronic human diseases, including neurodegenerative disorders. Based in Orange County, California, IMM along with Nuravax, a biotechnology company licensed IMM’s patented technology, is advancing MultiTEP, a universal vaccine platform technology that supports the development of multiple vaccine designs based on DNA, RNA, or recombinant proteins. For more information, please visit www.nuravax.com and follow us on LinkedIn.

Contacts

Nancy Lillie

Nancy.Lillie@pharmajet.com
1-888-900-4321 Option 3